United Therapeutics (UTHR) EBITDA Margin: History & Chart

United Therapeutics Corporation(UTHR)

Biotechnology · Silver Spring, MD

$494.22-3.05 (-0.61%)

Delayed quote: Sep 18, 2026, 2:15 PM EDT

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD

1,400 employees

www.unither.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martine A. Rothblatt

View full financials

UTHR EBITDA Margin Metrics

EBITDA MARGIN

50.36%

EBITDA MARGIN AVG TTM

47.55%

EBITDA MARGIN AVG 3Y

49.64%

EBITDA MARGIN AVG 5Y

50.84%

EBITDA MARGIN AVG 10Y

51.16%

EBITDA MARGIN AVG 15Y

49.97%

EBITDA MARGIN AVG 20Y

40.31%

CURRENT VS TTM AVG

+5.91%

CURRENT VS 3Y AVG

+1.45%

CURRENT VS 5Y AVG

-0.94%

CURRENT VS 10Y AVG

-1.57%

CURRENT VS 15Y AVG

+0.79%

CURRENT VS 20Y AVG

+24.95%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
United Therapeutics Corporation (UTHR)	$20.98B	50.36%	47.55%	49.64%	50.84%
STERIS plc (STE)vs ›	$20.13B	26.76%	25.68%	26.35%	25.75%
Viatris Inc. (VTRS)vs ›	$19.81B	0.95%	10.32%	17.98%	18.96%
Zimmer Biomet Holdings, Inc. (ZBH)vs ›	$18.51B	29.84%	29.78%	28.27%	25.91%
BioNTech SE (BNTX)vs ›	$24.16B	-9.29%	-23.11%	12.60%	20.38%
Medpace Holdings, Inc. (MEDP)vs ›	$17.06B	22.25%	22.41%	21.18%	20.68%
West Pharmaceutical Services, Inc. (WST)vs ›	$25.56B	24.13%	25.03%	27.36%	27.53%
Incyte Corporation (INCY)vs ›	$25.85B	27.93%	16.21%	17.95%	14.24%
Revvity, Inc. (RVTY)vs ›	$15.99B	23.07%	26.75%	30.05%	32.80%
Labcorp Holdings Inc. (LH)vs ›	$26.33B	15.75%	14.53%	14.10%	17.90%

NAME

MARKET CAP

EBITDA MARGIN

TTM

United Therapeutics Corporation (UTHR)

$20.98B

50.36%

47.55%

49.64%

50.84%

STERIS plc (STE)vs ›

$20.13B

26.76%

25.68%

26.35%

25.75%

Viatris Inc. (VTRS)vs ›

$19.81B

0.95%

10.32%

17.98%

18.96%

Zimmer Biomet Holdings, Inc. (ZBH)vs ›

$18.51B

29.84%

29.78%

28.27%

25.91%

BioNTech SE (BNTX)vs ›

$24.16B

-9.29%

-23.11%

12.60%

20.38%

Medpace Holdings, Inc. (MEDP)vs ›

$17.06B

22.25%

22.41%

21.18%

20.68%

West Pharmaceutical Services, Inc. (WST)vs ›

$25.56B

24.13%

25.03%

27.36%

27.53%

Incyte Corporation (INCY)vs ›

$25.85B

27.93%

16.21%

17.95%

14.24%

Revvity, Inc. (RVTY)vs ›

$15.99B

23.07%

26.75%

30.05%

32.80%

Labcorp Holdings Inc. (LH)vs ›

$26.33B

15.75%

14.53%

14.10%

17.90%

EBITDA Margin FAQ

What is the EBITDA margin for United Therapeutics Corporation (UTHR)?

The EBITDA margin for UTHR stock is 50.36%.

Is United Therapeutics Corporation's EBITDA margin high or low?

The EBITDA margin of 50.36% is in line with its 5-year average of 50.84%, around the middle of its 5-year range (38.41%–65.06%).

What is the TTM average EBITDA margin for United Therapeutics Corporation (UTHR)?

The TTM average EBITDA margin for UTHR stock is 47.55%.

What is the 3Y average EBITDA margin for United Therapeutics Corporation (UTHR)?

The 3Y average EBITDA margin for UTHR stock is 49.64%.

What is the 5Y average EBITDA margin for United Therapeutics Corporation (UTHR)?

The 5Y average EBITDA margin for UTHR stock is 50.84%.

What is the 10Y average EBITDA margin for United Therapeutics Corporation (UTHR)?

The 10Y average EBITDA margin for UTHR stock is 51.16%.

What is the 15Y average EBITDA margin for United Therapeutics Corporation (UTHR)?

The 15Y average EBITDA margin for UTHR stock is 49.97%.

What is the 20Y average EBITDA margin for United Therapeutics Corporation (UTHR)?

The 20Y average EBITDA margin for UTHR stock is 40.31%.

DATE	EBITDA MARGIN
2026-06-30	45.32%
2026-03-31	44.58%
2025-12-31	48.13%
2025-09-30	51.43%
2025-06-30	48.28%
2025-03-31	50.68%
2024-12-31	51.28%
2024-09-30	48.36%
2024-06-30	47.36%
2024-03-31	54.79%
2023-12-31	44.54%
2023-09-30	55.84%
2023-06-30	54.70%
2023-03-31	58.73%
2022-12-31	38.41%
2022-09-30	63.41%
2022-06-30	45.94%
2022-03-31	65.06%
2021-12-31	43.93%
2021-09-30	54.22%
2021-06-30	52.54%
2021-03-31	-13.80%
2020-12-31	20.37%
2020-09-30	61.27%
2020-06-30	42.29%
2020-03-31	50.27%
2019-12-31	24.43%
2019-09-30	48.84%
2019-06-30	62.04%
2019-03-31	-178.05%
2018-12-31	37.23%
2018-09-30	38.53%
2018-06-30	50.73%
2018-03-31	80.88%
2017-12-31	31.57%
2017-09-30	74.41%
2017-06-30	21.64%
2017-03-31	73.28%
2016-12-31	44.50%
2016-09-30	60.46%
2016-06-30	71.04%
2016-03-31	100.65%
2015-12-31	40.26%
2015-09-30	102.36%
2015-06-30	51.87%
2015-03-31	-1.98%
2014-12-31	54.14%
2014-09-30	-7.31%
2014-06-30	56.99%
2014-03-31	77.30%
2013-12-31	-7.18%
2013-09-30	37.16%
2013-06-30	46.32%
2013-03-31	41.69%
2012-12-31	55.74%
2012-09-30	36.14%
2012-06-30	49.60%
2012-03-31	55.52%
2011-12-31	35.05%
2011-09-30	53.52%
2011-06-30	76.46%
2011-03-31	25.78%
2010-12-31	7.68%
2010-09-30	39.13%
2010-06-30	47.57%
2010-03-31	28.57%
2009-12-31	2.33%
2009-09-30	14.65%
2009-06-30	-2.05%
2009-03-31	28.01%
2008-12-31	-173.31%
2008-09-30	25.41%
2008-06-30	27.70%
2008-03-31	25.76%
2007-12-31	-13.35%
2007-09-30	24.19%
2007-06-30	16.02%
2007-03-31	-18.26%
2006-12-31	7.80%
2006-09-30	29.29%
2006-06-30	29.86%
2006-03-31	9.11%
2005-12-31	37.02%
2005-09-30	45.83%
2005-06-30	39.18%
2005-03-31	32.01%
2004-12-31	32.06%
2004-09-30	31.38%
2004-06-30	22.25%
2004-03-31	-13.07%
2003-12-31	-21.21%
2003-09-30	-7.81%
2003-06-30	-15.95%
2003-03-31	-27.13%
2002-12-31	-21.82%
2002-09-30	-116.42%

DATE

EBITDA MARGIN

2026-06-30

45.32%

2026-03-31

44.58%

2025-12-31

48.13%

2025-09-30

51.43%

2025-06-30

48.28%

2025-03-31

50.68%

2024-12-31

51.28%

2024-09-30

48.36%

2024-06-30

47.36%

2024-03-31

54.79%

2023-12-31

44.54%

2023-09-30

55.84%

2023-06-30

54.70%

2023-03-31

58.73%

2022-12-31

38.41%

2022-09-30

63.41%

2022-06-30

45.94%

2022-03-31

65.06%

2021-12-31

43.93%

2021-09-30

54.22%

2021-06-30

52.54%

2021-03-31

-13.80%

2020-12-31

20.37%

2020-09-30

61.27%

2020-06-30

42.29%

2020-03-31

50.27%

2019-12-31

24.43%

2019-09-30

48.84%

2019-06-30

62.04%

2019-03-31

-178.05%

2018-12-31

37.23%

2018-09-30

38.53%

2018-06-30

50.73%

2018-03-31

80.88%

2017-12-31

31.57%

2017-09-30

74.41%

2017-06-30

21.64%

2017-03-31

73.28%

2016-12-31

44.50%

2016-09-30

60.46%

2016-06-30

71.04%

2016-03-31

100.65%

2015-12-31

40.26%

2015-09-30

102.36%

2015-06-30

51.87%

2015-03-31

-1.98%

2014-12-31

54.14%

2014-09-30

-7.31%

2014-06-30

56.99%

2014-03-31

77.30%

2013-12-31

-7.18%

2013-09-30

37.16%

2013-06-30

46.32%

2013-03-31

41.69%

2012-12-31

55.74%

2012-09-30

36.14%

2012-06-30

49.60%

2012-03-31

55.52%

2011-12-31

35.05%

2011-09-30

53.52%

2011-06-30

76.46%

2011-03-31

25.78%

2010-12-31

7.68%

2010-09-30

39.13%

2010-06-30

47.57%

2010-03-31

28.57%

2009-12-31

2.33%

2009-09-30

14.65%

2009-06-30

-2.05%

2009-03-31

28.01%

2008-12-31

-173.31%

2008-09-30

25.41%

2008-06-30

27.70%

2008-03-31

25.76%

2007-12-31

-13.35%

2007-09-30

24.19%

2007-06-30

16.02%

2007-03-31

-18.26%

2006-12-31

7.80%

2006-09-30

29.29%

2006-06-30

29.86%

2006-03-31

9.11%

2005-12-31

37.02%

2005-09-30

45.83%

2005-06-30

39.18%

2005-03-31

32.01%

2004-12-31

32.06%

2004-09-30

31.38%

2004-06-30

22.25%

2004-03-31

-13.07%

2003-12-31

-21.21%

2003-09-30

-7.81%

2003-06-30

-15.95%

2003-03-31

-27.13%

2002-12-31

-21.82%

2002-09-30

-116.42%

EBITDA Margin: 50.36%

UTHR EBITDA Margin

UTHR Average EBITDA Margin Chart

UTHR Current vs Average EBITDA Margin Chart

UTHR EBITDA Margin Metrics

UTHR Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

UTHR EBITDA Margin History

Related Metrics